Gynaecologist Bettina Wihlfahrt from Kiel has been using the osteolabs test procedure for some time. In the following example, she reports on a real case from her everyday practice. The first test with osteolabs took place on 21.03.2017 and resulted in a value of -1.23 ‰, which indicates an osteocatabolic metabolic state or already existing osteoporosis.

At the doctor's discretion, the patient was administered the hormone preparation Estramon Conti 30/95 from 21.08.2018 (green dot). Already 8 days after the intervention, the CBM value approaches the threshold value again, i.e. it is recognisable that the therapy is effective and the calcium loss could be reduced.

In a study supported by osteolabs, 16 postmenopausal women with osteoporosis diagnosed by DXA were treated once with Prolia® (denosumab), an antibody that inhibits the activation of osteoclasts. The patients were tested by osteolabs over several weeks and at regular intervals.

One day before the intervention with Prolia®, an average CBM value of -0.96 ‰ was determined using the osteolabs procedure, which confirmed the DXA diagnosis. After the intervention, the CBM value rose significantly above the threshold for osteoporosis, indicating increased calcium incorporation into the bone. The success of the Prolia® therapy was also evident weeks later in the subsequent tests.